The designated AMG type drugs appear to be for chronic diseases and may require weekly, monthly injections for years and most probably will be in the small volume wearable.
The rejection of the Humira bio similar patent, probably just means a delay for a few years which gives them time to prepare and in the meantime the SV wearable will establish its injection preference leader ship.
All good News
Amgen = billions in future revenues for Unilife, page-8
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)